VXRT
Vaxart Inc
1 day chart
About VXRT
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its programs include tablet vaccine candidates designed to protect against norovirus, coronavirus, seasonal influenza, and respiratory syncytial virus (RSV), as well as a therapeutic vaccine candidate for human papillomavirus (HPV). The Company’s product pipeline includes norovirus vaccine, an oral tablet vaccine candidate that protect against norovirus GI and norovirus GII, by targeting the norovirus GI.1 Norwalk strain and the norovirus GII.4 Sydney strain; influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. The Company is also developing therapeutic vaccines for cervical cancer.
Buy US stocks in Australia starting with VXRT. Open an account and start investing today!
$107.90M
-
0.00%
179.3K
$0.74
$0.71
$0.72
$2.35
$0.56
VXRT FAQs
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in VXRT
Related Stocks
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.